Table 3.
Antibiotic treatment prior to ceftazidime–avibactam therapy by indication
| Characteristic | cIAI (n = 90) |
cUTI (n = 103) |
HAP/VAP (n = 114) |
Other (n = 209)a |
Total (n = 516) |
|---|---|---|---|---|---|
| Any antibiotic(s) used for current infection before ceftazidime–avibactam, n (%) | |||||
| No | 16 (17.8) | 28 (27.2) | 14 (12.3) | 61 (29.2) | 119 (23.1) |
| Yes | 74 (82.2) | 75 (72.8) | 100 (87.7) | 148 (70.8) | 397 (76.9) |
| Reason for discontinuation per antibiotic, n (%) | |||||
| n | 73 | 75 | 100 | 141 | 389 |
| Perceived clinical failure/disease progression | 27 (37.0) | 14 (18.7) | 44 (44.0) | 49 (34.8) | 134 (34.4) |
| Isolation of a resistant bacteria | 44 (60.3) | 54 (72.0) | 50 (50.0) | 88 (62.4) | 236 (60.7) |
| Preference for empiric coverage | 5 (6.8) | 5 (6.7) | 11 (11.0) | 11 (7.8) | 32 (8.2) |
| Secondary infection requiring regimen change | 9 (12.3) | 1 (1.3) | 13 (13.0) | 12 (8.5) | 35 (9.0) |
| Any antibiotic for Gram-negative coverage used for current infection before ceftazidime–avibactam, n (%) | |||||
| No (ceftazidime–avibactam as first line) | 18 (20.0) | 31 (30.1) | 15 (13.2) | 62 (29.7) | 126 (24.4) |
| Yes (ceftazidime–avibactam as second line) | 72 (80.0) | 72 (69.9) | 99 (86.8) | 147 (70.3) | 390 (75.6) |
One reason per antibiotic—patients could receive several antibiotics
BSI bloodstream infection, cIAI complicated intra-abdominal infection, cUTI complicated urinary tract infection, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia
aIncludes patients with BSI/sepsis